Webcast ImageWebcast
Incyte Corporation at 21st Annual BioCentury NewsMakers Conference (Replay)
09/26/14 at 2:00 p.m. ET
Incyte Corporation at 21st Annual BioCentury NewsMakers Conference
Friday, September 26, 2014 2:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

The field of oncology is evolving rapidly and transforming how cancer is treated. We believe Incyte, rooted in rigorous science, is at the center of this transformation. Our pipeline includes innovative compounds in three major oncology areas: onco-inflammation, immuno-oncology and targeted therapies.

We believe our professional and financial resources, our experience and our prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders.


Recent News More >>
DateTitle 
September 08, 2014Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called Myeloproliferative Neoplasms (MPNs) and Honor MPN Heroes
Initiatives focus on increasing MPN Awareness Multiple patient education events scheduled throughout September Call for nominations – MPN Heroes™ recognition program WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2014-- September is Blood Cancer Awareness Month, and the MPN Coalition, a group of seven patient organizations, has designated September 11, 2014, as MPN Awareness Day. This day recognizes the approxi... 
Printer Friendly Version
September 08, 2014Incyte to Present at the 21st Annual BioCentury NewsMakers Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26, 2014 at 2:00 p.m. (EDT) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available. Investors interested in listening to the li... 
Printer Friendly Version
August 05, 2014FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 5, 2014-- Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The sNDA includes results from the RESPONSE Phase III trial, which were recently presen... 
Printer Friendly Version

2013 Annual Report
2013 Annual Report Download Documentation

2013 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.